Evidence map›Paper›PMID 31417927›Full record

ArticleWorld journal of clinical cases2019

Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study.

Maria C Rossi, Walter O Inojosa, Giuseppe Battistella, Antonella Carniato, Francesca Farina, Mario Giobbia, Rodolfo Fuser, Pier G Scotton

Open access · diamondAbstract read
In one paragraph

Article in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Past and future of HIV infection. A document based on expert opinion.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maria C RossiInfectious Diseases Unit, Treviso Hospital, Treviso 31100, Italy.
Walter O InojosaInfectious Diseases Unit, Treviso Hospital, Treviso 31100, Italy. walteromar.inojosa@aulss2.veneto.it.
Giuseppe BattistellaEpidemiology and Statistic Unit, Azienda ULSS 2 "Marca Trevigiana", Treviso 31100, Italy.
Antonella CarniatoInfectious Diseases Unit, Treviso Hospital, Treviso 31100, Italy.
Francesca FarinaInfectious Diseases Unit, Treviso Hospital, Treviso 31100, Italy.
Mario GiobbiaInfectious Diseases Unit, Treviso Hospital, Treviso 31100, Italy.
Rodolfo FuserInfectious Diseases Unit, Treviso Hospital, Treviso 31100, Italy.
Pier G ScottonInfectious Diseases Unit, Treviso Hospital, Treviso 31100, Italy.
Ca' Foncello Hospital · ITAzienda ULSS 9 TREVISO · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHighly active antiretroviral therapy (HAART) is provided free of charge to all human immunodeficiency virus (HIV) positive residents in Italy. As fixed dose coformulations (FDCs) are often more expensive in comparison to the same drugs administered separately in a multi-tablet regimen (MTR), we considered a cost-effective strategy involving patients in the switch from their FDCs to corresponding MTRs including generic antiretrovirals.

aimTo verify if this would affect the virological and immunological response in comparison to maintaining the FDC regimens.

methodsFrom January 2012 to December 2013, we assessed the eligibility of all the HIV-1 positive adults on stable HAART being treated at our hospital-based outpatient clinic in Treviso, Italy. Participants who accepted to switch from their FDC regimen to the corresponding MTR joined the MTR group, while those who maintained a FDC regimen joined the FDC group. Clinical data, including changes in HAART regimens, respective reasons why and adverse effects, were recorded at baseline and at follow-up visits occurring at weeks 24, 48 and 96. All participants were assessed for virological and immunological responses at baseline and at weeks 24, 48 and 96.

resultsTwo hundred and forty-three eligible HIV-1 adults on HAART were enrolled: 163 (67%) accepted to switch to a MTR, joining the MTR group, while 80 (33%) maintained their FDCs, joining the FDC group. In a parallel analysis, there were no significant differences in linear trend of distribution of HIV-RNA levels between the two groups and there were no significant odds in favour of a higher level of HIV-RNA in either group at any follow-up and on the overall three strata analysis. In a before-after analysis, both FDC and MTR groups presented no significant differences in distribution of HIV-RNA levels at either weeks 48

conclusionInvolving patients in the switch from their FDC regimens to the corresponding MTRs for economic reasons did not affect the effectiveness of antiretroviral therapy in terms of virological response and immunological recovery.

Indexed as

Fixed dose coformulation regimensFixed-dose coformulationsHighly active antiretroviral therapyHuman immunodeficiency virusMultitablet regimens

Identifiers

PMID31417927
PMCPMC6692266
OpenAlexW2965568241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.